Ind-Swift Labs.
Ticker > Company >

Ind-Swift Labs. share price

Ind-Swift Laboratories Ltd.

  67.23 K   69   12 NSE: INDSWFTLAB BSE: 532305 SECTOR: Pharmaceuticals & Drugs

353.25
-14.95 (-4.06%)
NSE: 02 Nov 04:07 PM

Buy on Zerodha

Price Summary

Today's High

₹ 374.75

Today's Low

₹ 346

52 Week High

₹ 426.6

52 Week Low

₹ 87.15

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 3121.37 Cr.

Enterprise Value

₹ 2724.08 Cr.

No. of Shares

8.84 Cr.

P/E

38.46

P/B

2.1

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  168.4

CASH

₹ 414.99 Cr.

DEBT

₹ 17.7 Cr.

Promoter Holding

42.93 %

EPS (TTM)

₹  9.18

Sales Growth

13.11%

ROE

3.46 %

ROCE

4%

Profit Growth

-83.38 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year13.11%
3 Year-17.97%
5 Year-5.78%

Profit Growth

1 Year-83.38%
3 Year0.07%
5 Year63.48%

ROE%

1 Year3.46%
3 Year29.37%
5 Year19.19%

ROCE %

1 Year4%
3 Year28.24%
5 Year20.97%

Debt/Equity

0.0129

Price to Cash Flow

-77.66

Interest Cover Ratio

36.7669

CFO/PAT (5 Yr. Avg.)

0.0712031785830365

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2026 42.93 0.00
Jun 2026 42.93 0.00
Mar 2026 42.99 0.00
Dec 2025 39.50 0.00
Sep 2025 39.50 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has significantly decreased its debt by 11.588 Cr.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 36.7669.
  • The company has an efficient Cash Conversion Cycle of 0.222300000000018 days.
  • Company has a healthy liquidity position with current ratio of 3.4781.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 11.8972921605141.

 Limitations

  • The company has shown a poor profit growth of 0.0665094062148652% for the Past 3 years.
  • The company has shown a poor revenue growth of -17.9681600242067% for the Past 3 years.
  • Company has negative cash flow from operations of -40.1937.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Net Sales 156.43 149.48 172.7 186.08 234.89
Total Expenditure 148.25 144.08 152.4 152.76 192.56
Operating Profit 8.19 5.4 20.31 33.32 42.33
Other Income 11.86 27.58 2.21 7.63 7.6
Interest 2.02 0.67 -2.44 0.71 1.33
Depreciation 6.98 8.84 8.08 7.58 7.77
Exceptional Items 0 -5.85 -5.15 -0.24 -0.58
Profit Before Tax 11.06 17.62 11.72 32.43 40.24
Tax 2.3 6.87 -3.22 7.98 9.21
Profit After Tax 8.76 10.74 14.94 24.44 31.03
Adjusted EPS (Rs) 1.07 1.32 1.72 2.81 3.57

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Net Sales 988.09 1151.96 1227.32 562.17 635.89
Total Expenditure 794.38 929.86 977.35 562.59 599.81
Operating Profit 193.71 222.09 249.97 -0.41 36.08
Other Income 42.5 33.28 45.31 68.75 57.11
Interest 95.55 92.17 51.1 2.92 1.4
Depreciation 130.97 57.36 53.3 24.48 30.57
Exceptional Items -1.69 -26.65 386.59 223.2 -11.01
Profit Before Tax 8 79.2 577.47 264.14 50.22
Tax 13.7 36.73 159.08 8.06 7.66
Net Profit -5.71 42.47 418.39 256.09 42.56
Adjusted EPS (Rs.) -0.97 7.19 70.81 37.25 4.9

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity and Liabilities
Share Capital 59.81 59.81 59.09 68.74 86.84
Total Reserves 572.75 615.54 863.16 1095.33 1283.86
Borrowings 839.07 744.43 3 22.54 12.11
Other N/C liabilities -32.7 -11.41 -30.61 -25.55 -30.35
Current liabilities 313.61 350.05 178.32 216.35 251.55
Total Liabilities 1752.53 1758.42 1072.95 1377.42 1604
Assets
Net Block 626.79 585 5.32 270.72 301.57
Capital WIP 9.31 7.71 0 0 10.2
Intangible WIP 1 0 0 0 2.21
Investments 110.68 85.12 165.94 229.55 318.55
Loans & Advances 3.89 4.1 353.84 81.17 94.37
Other N/C Assets 4.72 3.82 2.3 2.25 2.21
Current Assets 996.15 1072.67 545.54 793.73 874.91
Total Assets 1752.53 1758.42 1072.95 1377.42 1604
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Profit from operations 9.69 105.85 190.88 40.94 61.22
Adjustment 225.59 132.78 124.76 -36.92 -19.93
Changes in Assets & Liabilities -99.02 -55.95 -495.41 -42.75 -74.79
Tax Paid 0 0 0 -6.57 -6.7
Operating Cash Flow 136.26 182.67 -179.77 -45.3 -40.19
Investing Cash Flow 2.76 -13.69 -104.32 -109.67 -100.16
Financing Cash Flow -139.59 -168.41 699.86 77.44 145.26
Net Cash Flow -0.57 0.58 415.77 -77.53 4.9

Corporate Actions

Investors Details

PARTICULARS Sep 2025% Dec 2025% Mar 2026% Jun 2026% Sep 2026%
promoters 39.50 39.50 42.99 42.93 42.93
annie mehta 0.03 0.03 0.03 0.03 0.03
bhanavi mehta 0.01 0.01 0.01 0.01 0.01
deepti munjal 0.01 0.01 0.01 0.01 0.01
divya munjal 0.01 0.01 0.01 0.01 0.01
essix biosciences limited... 34.04 34.04 37.87 37.81 37.81
gopal munjal 0.43 0.43 0.41 0.41 0.41
himanshu jain 0.59 0.59 0.55 0.55 0.55
ishav mehta 0.01 0.01 0.01 0.01 0.01
meenakshi mehta 0.09 0.09 0.08 0.08 0.08
navrattan munjal - - - 1.16 1.16
neeta munjal 0.12 0.12 0.11 0.11 0.11
nidhi munjal 0.11 0.11 0.10 0.10 0.10
ravi mehta 0.13 0.13 0.12 0.12 0.12
rishav mehta 0.88 1.17 1.10 1.10 1.10
s. r. mehta 0.66 0.66 0.62 0.62 0.62
sahil munjal 0.03 0.03 0.03 0.03 0.03
saurabh munjal 0.01 0.01 0.01 0.01 0.01
sunita jain 0.39 0.39 0.37 0.37 0.37
v.r. mehta 0.42 0.42 0.39 0.39 0.39
n.r. munjal 1.24 1.24 1.17 - -
late neera mehta 0.28 - - - -
PARTICULARS Sep 2025% Dec 2025% Mar 2026% Jun 2026% Sep 2026%
investors 60.50 60.50 57.01 57.07 57.07
ark global emerging compa... - - - 1.13 1.40
ashokkumar chandak 2.98 2.99 2.70 2.21 2.42
chetan chandak - - - - 1.04
investor education and pr... - - 0.26 0.26 0.26
llp 0.26 0.19 0.15 0.17 0.10
manish chandak - - - - 1.01
nisarg ajaykumar vakharia... - - - 1.04 1.04
nova global opportunities... - - - 2.96 3.32
panchkula finvest private... 2.16 2.56 2.41 2.41 2.48
pranav joneja 1.24 1.47 1.44 1.44 1.44
rameshkumar javerchand ja... - 1.20 1.08 1.38 1.14
sharwan singh guleria 1.25 1.31 1.19 1.24 1.32
zaki abbas nasser - - 1.53 2.11 2.00
zeal global opportunities... 4.92 4.92 4.62 4.62 4.62
hcp investments 9.19 9.19 8.64 - -
investor education and pr... 0.27 0.27 - - -

Annual Reports

Title Link
Title Link
Annual Report 2025
Annual Report 2024
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit CARE
Credit CARE
Credit ICRA
Credit CARE
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q3FY26
Presentation Q2FY21
Presentation Q1FY27

Company News

Ind-Swift Labs. - Quaterly Results 30 Oct, 12:00 AM Ind-Swift Laboratories signs MoU with Him Infratech 29 Jul, 9:17 AM Ind-Swift Laboratories informs about press release 15 Jul, 5:18 PM Ind-Swift Laboratories informs about disclosures 22 Apr, 5:25 PM Ind-Swift Laboratories informs about disclosure 27 Feb, 11:41 AM Ind-Swift Laboratories informs about analyst meet 26 Feb, 5:32 PM Ind-Swift Laboratories to upgrade Samba facility with investment of Rs 40 crore 16 Feb, 3:42 PM Ind-Swift Laboratories informs about updates 1 Feb, 5:16 PM Ind-Swift Lab. - Quaterly Results 1 Feb, 12:00 AM Ind-Swift Laboratories informs about disclosure 18 Dec, 10:10 AM Ind-Swift Lab. - Quaterly Results 13 Aug, 6:23 PM Ind-Swift Lab. - Quaterly Results 13 Aug, 6:23 PM Ind-Swift Lab. - Quaterly Results 11 Aug, 9:07 PM Ind-Swift Lab. - Quaterly Results 11 Aug, 9:07 PM Ind-Swift Laboratories informs about disclosure 25 Jul, 11:52 AM Ind-Swift Laboratories informs about disclosure 4 Jul, 12:00 PM Ind-Swift Laboratories informs about communication to shareholders 21 Jun, 4:16 PM Ind-Swift Lab. - Quaterly Results 14 Feb, 11:16 AM Ind-Swift Lab. - Quaterly Results 14 Feb, 11:16 AM Ind-Swift Lab. - Quaterly Results 14 Feb, 11:16 AM Ind-Swift Laboratories informs about press release 22 Jan, 2:08 PM IND-Swift Laboratories informs about scheme of arrangement 4 Jan, 5:17 PM Ind-Swift Laboratories purchases land to set up new formulations facility 2 Jan, 10:11 AM Ind-Swift Laboratories acquires land to set up new R&D Centre in Punjab 10 Dec, 10:58 AM Ind-Swift Lab. - Quaterly Results 11 Nov, 6:59 PM Ind-Swift Lab. - Quaterly Results 11 Nov, 6:59 PM IND-Swift Laboratories informs about press release 23 Sep, 11:43 AM Ind-Swift Laboratories sets up new marketing office in New Delhi 23 Sep, 11:19 AM Ind-Swift Lab. - Quaterly Results 12 Aug, 7:44 PM Ind-Swift Lab. - Quaterly Results 12 Aug, 7:44 PM Ind-Swift Laboratories incorporates wholly owned subsidiary in UAE 20 May, 12:12 PM Ind-Swift Lab. - Quaterly Results 13 May, 7:47 PM Ind-Swift Lab. - Quaterly Results 13 May, 7:47 PM Ind-Swift Laboratories to incorporate wholly owned subsidiary in UAE 19 Apr, 12:15 PM Ind-Swift Laboratories informs about acquisition 19 Apr, 11:29 AM Ind-Swift Laboratories informs about disclosure 4 Apr, 10:02 AM Ind-Swift Laboratories informs about disclosure 3 Apr, 5:01 PM Ind-Swift Laboratories informs about disclosure 3 Apr, 12:15 PM Ind-Swift Laboratories informs about disclosure 30 Mar, 3:31 PM Ind-Swift Laboratories informs about disclosure 28 Mar, 10:58 AM Ind-Swift Lab. - Quaterly Results 12 Feb, 4:58 PM Ind-Swift Lab. - Quaterly Results 12 Feb, 4:58 PM Ind-Swift Lab. - Quaterly Results 12 Feb, 4:58 PM Ind-Swift Laboratories informs about disclosure 8 Feb, 2:51 PM Ind-Swift Laboratories collaborates with CSIR- IMTECH 30 Nov, 9:36 AM Ind-Swift Laboratories informs about outcome of board meeting 7 Nov, 5:18 PM Ind-Swift Laboratories informs about outcome of board meeting 7 Nov, 5:01 PM Ind-Swift Lab. - Quaterly Results 7 Nov, 4:13 PM Ind-Swift Lab. - Quaterly Results 7 Nov, 4:13 PM Ind-Swift Laboratories gets nod to sell API Business to Synthimed Labs 6 Sep, 2:30 PM

Ind-Swift Labs. Stock Price Analysis and Quick Research Report. Is Ind-Swift Labs. an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Ind-Swift Labs.. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Ind-Swift Labs. has a PE ratio of 38.4619572318279 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Ind-Swift Labs. has ROA of 2.8548% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Ind-Swift Labs. has a Current ratio of 3.4781.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Ind-Swift Labs. has a ROE of 3.4602%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Ind-Swift Labs. has a Debt to Equity ratio of 0.0129 which means that the company has low proportion of debt in its capital.

  • Sales growth: Ind-Swift Labs. has reported revenue growth of 13.1125% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Ind-Swift Labs. for the current financial year is 5.67420231691562%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Ind-Swift Labs. is Rs 0 and the yield is 0%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Ind-Swift Labs. is Rs 9.1844. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Ind-Swift Labs. in Ticker for free. Also, one can get the intrinsic value of Ind-Swift Labs. by using Valuation Calculators, which are available with a Finology ONE subscription. 

Ind-Swift Labs. FAQs

Q1. What is Ind-Swift Labs. share price today?
Ans: The current share price of Ind-Swift Labs. is Rs 353.25.

Q2. What is the market capitalisation of Ind-Swift Labs.?
Ans: Ind-Swift Labs. has a market capitalisation of Rs 3121.37203635 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Ind-Swift Labs.?
Ans: The PE ratio of Ind-Swift Labs. is 38.4619572318279 and the P/B ratio of Ind-Swift Labs. is 2.09765917269391, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Ind-Swift Labs. share?
Ans: The 52-week high share price of Ind-Swift Labs. is Rs 426.6, and the 52-week low share price of Ind-Swift Labs. is Rs 87.15.

Q5. Does Ind-Swift Labs. pay dividends?
Ans: Currently, Ind-Swift Labs. does not pay dividends. Dividend yield of Ind-Swift Labs. is around 0%.

Q6. What are the face value and book value of Ind-Swift Labs. shares?
Ans: The face value of Ind-Swift Labs. shares is Rs 10, while the book value per share of Ind-Swift Labs. is around Rs 168.402. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Ind-Swift Labs.?
Ans: Ind-Swift Labs. has a total debt of Rs 17.7015 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Ind-Swift Labs.?
Ans: The ROE of Ind-Swift Labs. is 3.4602% and ROCE of Ind-Swift Labs. is 3.9989%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Ind-Swift Labs. a good buy for the long term?
Ans: The Ind-Swift Labs. long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Ind-Swift Labs. undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Ind-Swift Labs. appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Ind-Swift Labs.’s financials?
Ans: You can review Ind-Swift Labs.’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Ind-Swift Labs.
X